Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9

Journal of the National Cancer Institute

Volumn 88, Issue 5, 1996, Pages 259-269

  Fitzsimmons, Sara A ^a   Workman, Paul ^a,c   Grever, Michael ^b,d   Paull, Kenneth ^b   Camalier, Richard ^b   Lewis, Alexander D ^a,e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; CYTOCHROME B5 REDUCTASE; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TISSUE SPECIFICITY;

ANTINEOPLASTIC AGENTS; AZIRIDINES; CYTOCHROME REDUCTASES; CYTOCHROME-B(5) REDUCTASE; HUMANS; INDOLEQUINONES; INDOLES; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029917028     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.5.259     Document Type: Article

References (43)

1. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 1993;12:73-82.
2. Walton MI, Bihhy MC, Double JA, Plumb JA, Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 1992;28A:1597-600.
3. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol 1992;44:409-12.
4. Robertson N, Haigh A, Adams GE, Stratford IJ. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 1994;30A:1013-9.
5. Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 1994;29:295-9.
6. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR, Double JA. In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 1992;65:359-64.
7. Smitskamp-Wilms E, Peters GJ, Pinedo HM, van Ark-Otte J, Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 1994;47:1325-32.
8. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 1994;6:461-75.
9. Verweij J, Aamdal S, Schellens J. Koier I, Lund B. Clinical studies with EO9. a new indoloquinone bioreductive alkylating cytoloxic agent. EORTC Early Clinical Trials Group. Oncol Res 1994;6:519-23.
10. Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 1994;86:906-12.
11. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993;12:83-101.
12. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW. Bioactivation of quinones by DT-diaphorase. molecular, biochemical, and chemical studies. Oncol Res 1994;6:493-500.
13. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA. Rubinstein L. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
14. Paull KD, Lin CM, Malspeis L, Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992;52:3892-900.
15. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV. Monks AP. et al. Neural computing in cancer drug development: predicting mechanism of action. Science 1992;258:447-51.
16. van Osdol WW, Myers TG, Paull KD, Kohn KW, Weinstein JN. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst 1994;86:1853-9.
17. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro drug discovery screen. Drug Develop Res 1995;34:91-109.
18. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
19. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem 1987;163:279]. Anal Biochem 1985; 150:76-85.
20. Ernster L, DT-diaphorase. Methods Enzymol 1967;10:309-17.
21. 2 distribution and bioreductive enzymes in human malignant brain tumours. Int J Radial Oncol Biol Phys 1994; 29:427-31.
22. Chomcynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
23. Horikoshi T, Dunenberg KD, Stadlbauer TH, Volkenandt M, Shea LC, Aigner K. et al. Quantitation of thymidylate synthase, dihydrofolate reducse, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 1992;52:108-16.
24. Jaiswal AK, McBride OW, Adesnik M, Neben DW. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J Biol Chem 1988;263:13572-8.
25. Shephard EA, Palmer CN, Segall HJ, Phillips IR. Quantification of cytochrome P450 reductase gene expression in human tissues. Arch Biochem Biophys 1992;294:168-72.
26. Gonzalez IL, Gorski JL, Campen TJ, Dorney DJ, Erickson JM, Sylvester JE. et al. Variation among human 28S ribosomal RNA genes. Proc Natl Acad Sci U S A 1985;82:7666-70.
27. Skehan P, Storeng R, Scudiero DA, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
28. Boyd MR. The future of new drug development. In: Neiderhuber J, editor. Current therapy in oncology. Philadelphia: B. C. Decker, Inc.,. 1993:11-22.
29. Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992;43:1657-69.
30. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075. SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 1994;15:1503-10.
31. 5 reductase. Cancer Res 1993;53:4907-12.
32. Plumb JA, Gerritsen M, Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone E09. Br J Cancer 1994;70:1136-43.
33. Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, et al. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int J Radial Oncol Biol Phys 1994;29:369-72.
34. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 1990;45:403-9.
35. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BF, Peters GJ. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 1995; 72:917-21.
36. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer. Proc Am Assoc Cancer Res 1993;34:144.
37. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990;50:7483-9.
38. Gustafson DL, Pritsos CA. Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol. Cancer Res 1992;52:6936-9.
39. Gustafson DL, Pritsos CA. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res 1993;53:5470-4.
40. Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, et al. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 1990;50:4692-7.
41. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994;56:134-9.
42. Workman P, Walton MI. Enzyme-directed bioreductive drug development. In: Adams GE, Breccia A, Fielden EM, Wardman P, editors. Selective activation of drugs by redox processes. New York: Plenum, 1990:173-91.
43. Workman P. Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 1992;22:631-7.